購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
huMPZL2-Q74* Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huMPZL2-Q74* Mouse
製品名
huMPZL2-Q74* Mouse
製品ID
C002132
系統名
C57BL/6Cya-Mpzl2tm1(hMPZL2*Q74X)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「huMPZL2-Q74* Mouse(カタログ番号C002132)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
EVA, EVA1, DFNB111
NCBI ID
染色体
Chr 11
MGI ID
さらに
系統詳細
Myelin protein zero-like 2 (MPZL2), also known as epithelial V-like antigen 1 (EVA1), is a single-pass type I transmembrane glycoprotein of the immunoglobulin superfamily that contains an Ig-like V-type domain in its extracellular region and mediates homophilic cell-cell adhesion [1]. MPZL2 is widely expressed; among fetal tissues the highest expression is found in the inner ear, whereas among adult tissues the highest levels are found in the thymus and lung [2]. Biallelic loss of MPZL2 function causes autosomal recessive non-syndromic deafness (DFNB111), in which patients present with early-onset, progressive sensorineural hearing loss without vestibular involvement [2-3]. Among DFNB111 patients of East Asian ancestry, most carry the c.220C>T (p.Q74*) variant, which is considered a founder mutation in East Asian populations [4-5]. MPZL2 has been regarded as a potential therapeutic target for DFNB111, and the relevant interventions remain at the preclinical stage, including adeno-associated virus (AAV)-mediated human MPZL2 gene supplementation and base editing to correct the c.220C>T mutation [5-6].
The huMPZL2-Q74* mouse is a humanized model in which the sequence from upstream of the mouse Mpzl2 start codon to downstream of the 3'UTR was replaced with the corresponding sequence of the human MPZL2 gene, and the p.Q74* (CAG to TAG) mutation was introduced into exon 2 of the human MPZL2 gene. This model can be used for studying the pathogenesis of DFNB111, as well as for screening, development, and preclinical in vivo evaluation of MPZL2-targeted therapies.
参考文献
Güttinger M, Sutti F, Panigada M, et al. Epithelial V-like antigen (EVA), a novel member of the immunoglobulin superfamily, expressed in embryonic epithelia with a potential role as homotypic adhesion molecule in thymus histogenesis. J Cell Biol. 1998;141(4):1061-1071. doi:10.1083/jcb.141.4.1061
Wesdorp M, Murillo-Cuesta S, Peters T, et al. MPZL2, encoding the epithelial junctional protein myelin protein zero-like 2, is essential for hearing in man and mouse. Am J Hum Genet. 2018;103(1):74-88. doi:10.1016/j.ajhg.2018.05.011
Bademci G, Abad C, Incesulu A, et al. MPZL2 is a novel gene associated with autosomal recessive nonsyndromic moderate hearing loss. Hum Genet. 2018;137(6-7):479-486. doi:10.1007/s00439-018-1901-4
Li W, Guo L, Chen B, Shu Y, Li H. MPZL2 variant analysis with whole exome sequencing in a cohort of Chinese hearing loss patients. Int J Pediatr Otorhinolaryngol. 2023;171:111635. doi:10.1016/j.ijporl.2023.111635
Hu SW, Jeong S, Jiang L, et al. PAM-flexible adenine base editing rescues hearing loss in a humanized MPZL2 mouse model harboring an East Asian founder mutation. Nat Commun. 2025;16:7186. doi:10.1038/s41467-025-62562-8
Jang SH, Song HG, Joo SY, et al. Gene supplementation with precise transgene expression rescues hearing loss in a mouse model with an Mpzl2 East Asian founder variant. Mol Ther. 2026;34(1):216-231. doi:10.1016/j.ymthe.2025.10.005
系統作製戦略
The sequence from upstream of the mouse Mpzl2 start codon to downstream of the 3'UTR was replaced with the corresponding sequence of the human MPZL2 gene, and the p.Q74* (CAG to TAG) mutation was introduced into exon 2 of the human MPZL2 gene.

Figure 1. Gene editing strategy of huMPZL2-Q74* mice.
適用分野
Pathogenesis studies of DFNB111 and other hereditary hearing loss;
Research and development, screening, and preclinical in vivo evaluation of MPZL2-targeted therapies and gene therapy strategies.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
